GlassScriptPhysician profile
Robert Paul Finkelstein
NPI 1336178953
$421,409.68
in general payments reported to CMS, 2019-2025
49 companies · $51K in 2025
The $51K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $31K · 2021: $62K · 2022: $61K · 2023: $91K · 2024: $69K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $179K · Food and Beverage: $13K · Travel and Lodging: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,498 · Consulting Fee: $1,403 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $179,381.75 |
| Food and Beverage | $13,130.23 |
| Travel and Lodging | $10,274.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,498.00 |
| Consulting Fee | $1,402.50 |
| Education | $281.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171,103.01 | 2019-2025 | |
| Galderma Laboratories, L.P. | $60,551.24 | 2019-2025 | Aklief, Epsolay, Oracea |
| Ucb, INC. | $48,871.44 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $45,461.91 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $42,471.72 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $18,623.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,427.86 | 2022-2025 | Spevigo |
| Pfizer INC. | $6,687.70 | 2019-2025 | |
| Amgen INC. | $3,646.57 | 2019-2025 | Otezla, Otezla |
| Journey Medical Corporation | $1,391.93 | 2020-2023 | |
| Merz North America, INC. | $1,271.63 | 2019-2025 | Xeomin |
| Janssen Biotech, INC. | $1,127.67 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $1,006.77 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $798.25 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $767.58 | 2019-2025 | Adbry, Anzupgo, Spevigo |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $657.08 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $577.22 | 2019-2025 | Cabtreo, Siliq |
| E.R. Squibb & Sons, L.L.C. | $507.23 | 2021-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $368.93 | 2019-2024 | |
| Biofrontera INC. | $364.53 | 2020-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $356.71 | 2022-2024 | Vtama |
| Epi Health, LLC | $311.90 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $248.73 | 2019-2021 | |
| Allergan, INC. | $246.47 | 2019-2022 | |
| Almirall LLC | $205.01 | 2020-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $165.55 | 2023-2025 | Zoryve |
| Encore Dermatology INC. | $164.02 | 2019-2020 | |
| Kerecis Limited | $129.55 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $116.71 | 2019 | |
| Vyne Pharmaceuticals INC. | $87.72 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $68.99 | 2023 | |
| Revance Therapeutics, INC. | $68.73 | 2024 | Daxxify |
| Organogenesis INC. | $65.86 | 2024 | Affinity |
| Sebela Pharmaceuticals INC. | $53.75 | 2020-2022 | |
| Sandoz INC. | $52.78 | 2020 | |
| Verrica Pharmaceuticals INC. | $48.96 | 2023-2024 | Ycanth |
| Botanix Sb INC | $46.42 | 2025 | Sofdra |
| Krystal Biotech INC | $41.35 | 2024 | Vyjuvek |
| Celgene Corporation | $39.14 | 2019 | |
| Paratek Pharmaceuticals, INC. | $36.76 | 2022-2023 | Nuzyra |
| Kyowa Kirin, INC. | $33.40 | 2023 | Poteligeo |
| Organon LLC | $33.09 | 2025 | |
| Dermira, INC. | $19.33 | 2019 | |
| Aclaris Therapeutics, INC. | $19.19 | 2019 | |
| Lnhc, INC | $16.00 | 2025 | Zelsuvmi |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Smith+Nephew, INC. | $12.50 | 2019 | |
| Strata Skin Sciences, INC. | $11.59 | 2020 | |
| Promius Pharma LLC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Finkelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.